These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. Goyal V; Grimwood K; Byrnes CA; Morris PS; Masters IB; Ware RS; McCallum GB; Binks MJ; Marchant JM; van Asperen P; O'Grady KF; Champion A; Buntain HM; Petsky H; Torzillo PJ; Chang AB Lancet; 2018 Oct; 392(10154):1197-1206. PubMed ID: 30241722 [TBL] [Abstract][Full Text] [Related]
3. Which patients with respiratory disease need long-term azithromycin? Alchakaki A; Cramer C; Patterson A; Soubani AO Cleve Clin J Med; 2017 Oct; 84(10):755-758. PubMed ID: 28985171 [No Abstract] [Full Text] [Related]
4. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. Altenburg J; de Graaff CS; Stienstra Y; Sloos JH; van Haren EH; Koppers RJ; van der Werf TS; Boersma WG JAMA; 2013 Mar; 309(12):1251-9. PubMed ID: 23532241 [TBL] [Abstract][Full Text] [Related]
5. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Valery PC; Morris PS; Byrnes CA; Grimwood K; Torzillo PJ; Bauert PA; Masters IB; Diaz A; McCallum GB; Mobberley C; Tjhung I; Hare KM; Ware RS; Chang AB Lancet Respir Med; 2013 Oct; 1(8):610-620. PubMed ID: 24461664 [TBL] [Abstract][Full Text] [Related]
6. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Wong C; Jayaram L; Karalus N; Eaton T; Tong C; Hockey H; Milne D; Fergusson W; Tuffery C; Sexton P; Storey L; Ashton T Lancet; 2012 Aug; 380(9842):660-7. PubMed ID: 22901887 [TBL] [Abstract][Full Text] [Related]
7. Azithromycin in bronchiectasis: when should it be used? Wilson R; Wells AU Lancet; 2012 Aug; 380(9842):627-9. PubMed ID: 22901872 [No Abstract] [Full Text] [Related]
14. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Davies G; Wilson R Thorax; 2004 Jun; 59(6):540-1. PubMed ID: 15170047 [No Abstract] [Full Text] [Related]
15. Is cardiovascular risk a concern when prescribing azithromycin? Sutton SS JAAPA; 2017 Jan; 30(1):11-13. PubMed ID: 28033168 [TBL] [Abstract][Full Text] [Related]
16. The newer macrolides: azithromycin and clarithromycin. Zuckerman JM Infect Dis Clin North Am; 2000 Jun; 14(2):449-62, x. PubMed ID: 10829265 [TBL] [Abstract][Full Text] [Related]
17. The role of azithromycin in patients with cystic fibrosis. Yousef AA; Jaffe A Paediatr Respir Rev; 2010 Jun; 11(2):108-14. PubMed ID: 20416547 [TBL] [Abstract][Full Text] [Related]
18. Do cystic fibrosis patients on azithromycin need electrocardiogram monitoring? Sharpton R; Condren M; O'Neal K; Lloyd A; McIntosh H Pulm Pharmacol Ther; 2017 Apr; 43():55-56. PubMed ID: 28219728 [No Abstract] [Full Text] [Related]
19. Changes in QT intervals after azithromycin-containing antibiotic therapy in patients with NTM lung disease. Shin B; Park HY; Koh WJ Int J Tuberc Lung Dis; 2014 Nov; 18(11):1385. PubMed ID: 25299875 [No Abstract] [Full Text] [Related]
20. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults. Sopena N; Martínez-Vázquez C; Rodríguez-Suárez JR; Segura F; Valencia A; Sabrià M J Chemother; 2004 Feb; 16(1):102-3. PubMed ID: 15078008 [No Abstract] [Full Text] [Related] [Next] [New Search]